Status | Study |
Not yet recruiting |
Study Name: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Condition: Peripheral T Cell Lymphoma Date: 2016-11-03 Interventions: Drug: chidamide 30mg po twice |
Recruiting |
Study Name: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-10-21 Interventions: Drug: Chidamide Chidamide is given to the patients as described, and drug concentration is measured in p |
Not yet recruiting |
Study Name: Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-07-24 Interventions: Drug: Chidamide with ICE regimen Chidamide and ICE regimen, dosage described in arm description |
Not yet recruiting |
Study Name: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients Condition: Peripheral T-cell Lymphoma Date: 2016-06-17 Interventions: Drug: Chidamide In the lead-in |
Recruiting |
Study Name: Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-04-19 Interventions: Drug: Chidamide |
Recruiting |
Study Name: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Condition: Peripheral T-Cell Lymphoma Date: 2015-12-25 Interventions: Drug: SP-02L (darinaparsin for injection) Darinaparsin 300 mg/m2 once daily for 5 consecutive days every |
Recruiting |
Study Name: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Condition: Peripheral T-cell Lymphomas Date: 2015-07-26 Interventions: Drug: GDP GDP is a a combinati |
Active, not recruiting |
Study Name: Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2013-12-04 Interventions: Drug: Pralatrexate injection Dietary Suppl |
Terminated |
Study Name: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Condition: Peripheral T-Cell Lymphoma Date: 2013-04-24 Interventions: Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day |
Active, not recruiting |
Study Name: Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients Condition: Peripheral T-cell Lymphoma Date: 2013-03-28 Interventions: Drug: Romidepsin, Gemcitabine Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15 |